—
Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness and weight loss. Risk factors include exposure to radiation, chemicals and saw dust. Treatment includes surgery, chemotherapy and radiation therapy.Get Sample Report @ https://www.wiseguyreports.com/sample-request/740554-hairy-cell-leukemia-pipeline-review-h2-2016
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Hairy Cell Leukemia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hairy Cell Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hairy Cell Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hairy Cell Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 8, 1, 1, 2 and 1 respectively.Hairy Cell Leukemia.
Hairy Cell Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hairy Cell Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hairy Cell Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hairy Cell Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hairy Cell Leukemia (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hairy Cell Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hairy Cell Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Hairy Cell Leukemia Overview 7
Therapeutics Development 8
Pipeline Products for Hairy Cell Leukemia - Overview 8
Hairy Cell Leukemia - Therapeutics under Development by Companies 9
Hairy Cell Leukemia - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Hairy Cell Leukemia - Products under Development by Companies 14
Hairy Cell Leukemia - Companies Involved in Therapeutics Development 15
AbbVie Inc 15
ARA Healthcare Pvt. Ltd. 16
Astellas Pharma Inc. 17
Biogenomics Limited 18
F. Hoffmann-La Roche Ltd. 19
Incyte Corporation 20
Juno Therapeutics Inc. 21
MedImmune LLC 22
Novartis AG 23
Hairy Cell Leukemia - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
(dezapelisib + itacitinib adipate) - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
AGS-67E - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
ARABS-4 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
dezapelisib - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
ibrutinib - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
INCB-50465 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
interferon alfa-2a - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
interferon alfa-2b - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
interferon alfa-2b - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
itacitinib adipate - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
JCAR-015 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
moxetumomab pasudotox - Drug Profile 79
Product Description 79
Mechanism Of Action 79
Access Report @ https://www.wiseguyreports.com/reports/740554-hairy-cell-leukemia-pipeline-review-h2-2016
Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts
Contact Info:
Name: Norah Trent
Email: Send Email
Organization: WiseGuy Reports
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India
Phone: +1-646-845-9349
Website: http://www.wiseguyreports.com
Release ID: 146570
Google
RSS